|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
M Bengtsson, J Gordon, L Flores-Romo, JA Cairns, B Smedmyr, G Oberg, B Simonsson and TH Totterman
Department of Clinical Immunology, University Hospital, Uppsala, Sweden.
The serum levels of IgE and the soluble cleavage product of CD23 (sCD23)
were prospectively monitored for up to 1 year after transplantation in 34
patients who underwent autologous (n = 33) or syngeneic (n = 1) bone marrow
transplantation (BMT). In 25 patients (74%), a transient IgE peak (two- to
2,750-fold increase) appeared in the serum 3 to 4 weeks after BMT. In 18
patients (51%), a two- to 125- fold increase in sCD23 coincided with the
IgE peak. In only three patients was a sCD23 peak observed without a
concomitant increase in IgE. The sCD23 increment preceded the IgE peak in
each individual case. During the period of increased sCD23 serum levels,
the absolute numbers of circulating B cells and other cell types expressing
surface CD23 were extremely low. The biologic significance of these
findings is discussed in light of present knowledge of regulation of B-cell
growth and differentiation with special reference to the role of sCD23 as a
multifunctional cytokine.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1989 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
